Atherosclerosis Drugs Market
Atherosclerosis Drugs Market Analysis by Anti-platelet Medications, Cholesterol-lowering Medications, Beta Blockers, ACE Inhibitors, Calcium Channel Blockers, and Diuretics from 2023 to 2033
Analysis of Atherosclerosis Drugs Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Table of Content
1. Preface 1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary : Global Market 4. Market Overview 4.1. Introduction 4.1.1. Drug Type Definition 4.1.2. Industry Evolution / Developments 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.1.1. Increase in Prevalence of Atherosclerosis & Cardiovascular Diseases 4.3.1.2. Development of New Treatments 4.3.1.3. Rising Awareness about Cardiovascular Diseases 4.3.2. Restraints 4.3.2.1. Availability of Generic Products 4.3.2.2. Low Diagnostic Rate 4.3.3. Opportunities 4.4. Global Market Analysis and Forecast, 2023–2033 5. Market Outlook 5.1. Clinical Trial Pipeline Analysis 5.2. Disease Prevalence & Incidence Rate globally with key countries 5.3. Brand Analysis 6. Global Market Analysis and Forecast, By Drug Class 6.1. Introduction & Definition 6.1.1. Key Findings / Developments 6.2. Global Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033 6.2.1. Anti-platelet Medications 6.2.2. Cholesterol Lowering Medications 6.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives 6.2.4. Beta Blockers 6.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors 6.2.6. Calcium Channel Blockers 6.2.7. Diuretics 6.2.8. Others 6.3. Global Market Attractiveness, by Drug Class 7. Global Market Analysis and Forecast, By Distribution Channel 7.1. Introduction & Definition 7.1.1. Key Findings / Developments 7.2. Global Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033 7.2.1. Retail Pharmacies 7.2.2. Hospital Pharmacies 7.2.3. Online Pharmacies 7.3. Global Market Attractiveness, by Distribution Channel 8. Global Market Analysis and Forecast, By Region 8.1. Key Findings 8.2. Global Market Revenue (US$ Mn) Forecast, by Region 8.2.1. North America 8.2.2. Europe 8.2.3. Asia Pacific 8.2.4. Latin America 8.2.5. Middle East & Africa 8.3. Global Market Attractiveness, by region 9. North America Market Analysis and Forecast 9.1. Introduction 9.1.1. Key Findings 9.2. North America Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033 9.2.1. Anti-platelet Medications 9.2.2. Cholesterol Lowering Medications 9.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives 9.2.4. Beta Blockers 9.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors 9.2.6. Calcium Channel Blockers 9.2.7. Diuretics 9.2.8. Others 9.3. North America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033 9.3.1. Retail Pharmacies 9.3.2. Hospital Pharmacies 9.3.3. Online Pharmacies 9.4. North America Market Revenue (US$ Mn) Forecast, by Country, 2023–2033 9.4.1. U.S. 9.4.2. Canada 9.5. North America Market Attractiveness 9.5.1. By Drug Type 9.5.2. By Distribution Channel 9.5.3. By Country 10. Europe Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. Europe Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033 10.2.1. Anti-platelet Medications 10.2.2. Cholesterol Lowering Medications 10.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives 10.2.4. Beta Blockers 10.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors 10.2.6. Calcium Channel Blockers 10.2.7. Diuretics 10.2.8. Others 10.3. Europe Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033 10.3.1. Retail Pharmacies 10.3.2. Hospital Pharmacies 10.3.3. Online Pharmacies 10.4. Europe Market Revenue (US$ Mn) Forecast, by Country Sub/region, 2023–2033 10.4.1. Germany 10.4.2. U.K. 10.4.3. France 10.4.4. Spain 10.4.5. Italy 10.4.6. Rest of Europe 10.5. Europe Market Attractiveness 10.5.1. By Drug Type 10.5.2. By Distribution Channel 10.5.3. By Country/Sub-region 11. Asia Pacific Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Asia Pacific Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033 11.2.1. Anti-platelet Medications 11.2.2. Cholesterol lowering medications 11.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives 11.2.4. Beta blockers 11.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors 11.2.6. Calcium Channel Blockers 11.2.7. Diuretics 11.2.8. Others 11.3. Asia Pacific Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033 11.3.1. Retail Pharmacies 11.3.2. Hospital Pharmacies 11.3.3. Online Pharmacies 11.4. Asia Pacific Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033 11.4.1. China 11.4.2. Japan 11.4.3. India 11.4.4. Australia & New Zealand 11.4.5. Rest of Asia Pacific 11.5. Asia Pacific Market Attractiveness 11.5.1. By Drug Type 11.5.2. By Distribution Channel 11.5.3. By Country/Sub-region 12. Latin America Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Latin America Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033 12.2.1. Anti-platelet Medications 12.2.2. Cholesterol Lowering Medications 12.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives 12.2.4. Beta blockers 12.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors 12.2.6. Calcium Channel Blockers 12.2.7. Diuretics 12.2.8. Others 12.3. Latin America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033 12.3.1. Retail Pharmacies 12.3.2. Hospital Pharmacies 12.3.3. Online Pharmacies 12.4. Latin America Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033 12.4.1. Brazil 12.4.2. Mexico 12.4.3. Rest of Latin America 12.5. Latin America Market Attractiveness 12.5.1. By Drug Type 12.5.2. By Distribution Channel 12.5.3. By Country/Sub-region 13. Middle East & Africa Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Middle East & Africa Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033 13.2.1. Anti-platelet medications 13.2.2. Cholesterol Lowering Medications 13.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives 13.2.4. Beta blockers 13.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors 13.2.6. Calcium Channel Blockers 13.2.7. Diuretics 13.2.8. Others 13.3. Middle East & Africa Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033 13.3.1. Retail Pharmacies 13.3.2. Hospital Pharmacies 13.3.3. Online Pharmacies 13.4. Middle East & Africa Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033 13.4.1. GCC 13.4.2. South Africa 13.4.3. Rest of Middle East & Africa 13.5. Middle East & Africa Market Attractiveness 13.5.1. By Drug Type 13.5.2. By Distribution Channel 13.5.3. By Country/Sub-region 14. Competition Landscape 14.1. Market Player – Competition Matrix (By Tier and Size of companies) 14.2. Key Company’s Market Ranking Analysis 14.3. Company Profiles 14.3.1. GlaxoSmithKline Plc 14.3.1.1. Company Overview 14.3.1.2. Company Financials 14.3.1.3. Growth Strategies 14.3.1.4. SWOT Analysis 14.3.2. Sanofi 14.3.2.1. Company Overview 14.3.2.2. Company Financials 14.3.2.3. Growth Strategies 14.3.2.4. SWOT Analysis 14.3.3. Hoffmann-La Roche Ltd 14.3.3.1. Company Overview 14.3.3.2. Company Financials 14.3.3.3. Growth Strategies 14.3.3.4. SWOT Analysis 14.3.4. Bayer AG 14.3.4.1. Company Overview 14.3.4.2. Company Financials 14.3.4.3. Growth Strategies 14.3.4.4. SWOT Analysis 14.3.5. Novartis AG 14.3.5.1. Company Overview 14.3.5.2. Company Financials 14.3.5.3. Growth Strategies 14.3.5.4. SWOT Analysis 14.3.6. Merck & Co., Inc. (Merck Sharp & Dohme Corp) 14.3.6.1. Company Overview 14.3.6.2. Company Financials 14.3.6.3. Growth Strategies 14.3.6.4. SWOT Analysis 14.3.7. Janssen Pharmaceuticals, Inc. (Johnson & Johnson) 14.3.7.1. Company Overview 14.3.7.2. Company Financials 14.3.7.3. Growth Strategies 14.3.7.4. SWOT Analysis 14.3.8. Mylan N.V. 14.3.8.1. Company Overview 14.3.8.2. Company Financials 14.3.8.3. Growth Strategies 14.3.8.4. SWOT Analysis 14.3.9. Amgen Inc. 14.3.9.1. Company Overview 14.3.9.2. Company Financials 14.3.9.3. Growth Strategies 14.3.9.4. SWOT Analysis 14.3.10. Pfizer, Inc. 14.3.10.1. Company Overview 14.3.10.2. Company Financials 14.3.10.3. Growth Strategies 14.3.10.4. SWOT Analysis
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Atherosclerosis Pipeline Analysis
Table 02: Atherosclerosis Pipeline Analysis
Table 03: Global Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033
Table 04: Global Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 05: Global Market Revenue (US$ Mn) Forecast, by Region, 2023–2033
Table 06: North America Market Revenue (US$ Mn) Forecast, by Drug Class 2023–2033
Table 07: North America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 08: North America Market Revenue (US$ Mn) Forecast, by Country, 2023–2033
Table 09: Europe Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033
Table 10: Europe Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 11: Europe Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 12: Asia Pacific Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033
Table 13: Asia Pacific Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 14: Asia Pacific Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 15: Latin America Market Revenue (US$ Mn) Forecast, by Drug Class 2023–2033
Table 16: Latin America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 17: Latin America Market Revenue (US$ Mn) Forecast, by Country / Sub-region, 2023–2033
Table 18: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Drug Class, 2023–2033
Table 19: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 20: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Revenue (US$ Mn) and Distribution (%), by Region, 2023 and 2033
Figure 02: Global Market Revenue (US$ Mn), by Drug Class, 2023
Figure 03: Global Market Revenue Share Analysis, by Drug Class, 2023
Figure 04: Market Overview
Figure 05: Global Market Revenue Share, by Drug Class, 2023
Figure 06: Global Market Revenue Share, by Distribution Channel, 2023
Figure 07: Global Market Revenue Share, by Region, 2023
Figure 08: Global Market Revenue (US$ Mn) Forecast, 2023–2033
Figure 09: Global Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 10: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anti-platelet Medications, 2023–2033
Figure 11: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cholesterol Lowering Medications, 2023–2033
Figure 12: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Fibric Acid and Omega-3 Fatty Acid Derivatives, 2023–2033
Figure 13: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Beta Blockers, 2023–2033
Figure 14: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Angiotensin-converting Enzyme (ACE) Inhibitors, 2023–2033
Figure 15: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Calcium Channel Blockers, 2023–2033
Figure 16: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Diuretics, 2023–2033
Figure 17: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2023–2033
Figure 18: Global Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 19: Global Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 20: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth(%) Projection, by Retail Pharmacies, 2023–2033
Figure 21: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2023–2033
Figure 22: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2023–2033
Figure 23: Global Market Attractiveness Analysis, by Distribution Channel, 2023–2033
Figure 24: Global Market Revenue Share Analysis, by Region, 2023 and 2033
Figure 25: Global Market Attractiveness Analysis, by Region, 2023–2033
Figure 26: North America Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033
Figure 27: North America Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 28: North America Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 29: North America Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 30: North America Market Attractiveness Analysis, by Distribution Channel, 2023 -2033
Figure 31: North America Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 32: North America Market Attractiveness Analysis, by Country/Sub-region, 2023–2033
Figure 33: Europe Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033
Figure 34: Europe Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 35: Europe Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 36: Europe Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 37: Europe Market Attractiveness Analysis, by Distribution Channel, 2023–2033
Figure 38: Europe Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 39: Europe Market Attractiveness Analysis, by Country/Sub-region, 2023–2033
Figure 40: Asia Pacific Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033
Figure 41: Asia Pacific Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 42: Asia Pacific Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 43: Asia Pacific Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 44: Asia Pacific Market Attractiveness Analysis, by Distribution Channel, 2023 -2033
Figure 45: Asia Pacific Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 46: Asia Pacific Market Attractiveness Analysis, by Country/Sub-region, 2023–2033
Figure 47: Latin America Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033
Figure 48: Latin America Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 49: Latin America Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 50: Latin America Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 51: Latin America Market Attractiveness Analysis, by Distribution Channel, 2023 -2033
Figure 52: Latin America Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 53: Latin America Market Attractiveness Analysis, by Country/Sub-region, 2023–2033
Figure 54: Middle East & Africa Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033
Figure 55: Middle East & Africa Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 56: Middle East & Africa Market Attractiveness Analysis, by Drug Class, 2023–2033
Figure 57: Middle East & Africa Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 58: Middle East & Africa Market Attractiveness Analysis, by Distribution Channel, 2023 -2033
Figure 59: Middle East & Africa Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 60: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2023–2033
Figure 61: Market Position Analysis, 2023, by Tier and Size of the Company
Figure 62: GlaxoSmithKline plc (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 63: GlaxoSmithKline plc Breakdown of Net Sales (%), by Region/Country, 2023
Figure 64: GlaxoSmithKline plc Revenue Breakdown of Net Sales (%), by Business segment, 2023
Figure 65: GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 66: Sanofi (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 65: GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 68: Sanofi Revenue Breakdown of Net Sales (%), by Pharmaceutical Business segment, 2023
Figure 69: Sanofi R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2023–2023
Figure 70: F. Hoffmann-La Roche Ltd Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 71: F. Hoffmann-La Roche Ltd Breakdown of Net Sales (%), by Region, 2023
Figure 72: F. Hoffmann-La Roche Ltd Breakdown of Net Sales (%), by Pharmaceutical Division, 2023
Figure 73: F. Hoffmann-La Roche Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 74: Bayer AG, Pharmaceutical Revenue (US$ Mn) and Y-o-Y Growth (%), 2023–2023
Figure 75: Bayer AG Breakdown of Net Sales (%), by Region, 2023
Figure 76: Bayer AG Revenue Breakdown of Net Sales (%), by Business segment, 2023
Figure 77: Bayer AG, pharmaceutical segment R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 78: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 79: Novartis AG Breakdown of Net Sales (%) of Innovative Medicines Business Segment, by Region/Country, 2023
Figure 80: Novartis AG Revenue Breakdown of Net Sales (%), by Innovative Medicines Segment, 2023
Figure 81: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 82: Merck & Co., Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 83: Merck & Co., Inc. Breakdown of Net Sales (%), by Region/Country, 2023
Figure 84: Merck & Co., Inc. Revenue Breakdown of Net Sales (%), by Segment, 2023
Figure 85: Merck & Co., Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 86: Johnson & Johnson Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2023–2023
Figure 87: Johnson & Johnson Breakdown of Net Sales (%), of Pharmaceutical Segment by Region/Country, 2023
Figure 88: Johnson & Johnson Revenue Breakdown of Net Sales (%), by Pharmaceutical Segment, 2023
Figure 89: Johnson & Johnson, Pharmaceutical Segment R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2023–2023
Figure 90: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 91: Mylan N.V. R&D Expenses (US$ Mn), 2023–2023
Figure 92: Mylan N.V. Breakdown of Net Sales, by Region, 2023
Figure 93: Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 94: Amgen, Inc. Breakdown of Net Sales (%), by Region/Country, 2023
Figure 95: Amgen Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), by Segment 2014–2023
Figure 96: Pfizer, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Figure 97: Pfizer, Inc. Breakdown of Net Sales, by Geography, 2023
Figure 98: Pfizer, Inc. Breakdown of Net Sales, by Business Segment (%), 2023
Figure 99: Pfizer, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2023
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request